Side Effects of Brolucizumab

Código QR

Side Effects of Brolucizumab

Abstract Age-related macular degeneration and its complication, subretinal neovascularization, are common causes of progressive, irreversible impairment of central vision. Anti-vascular endothelial growth factor (anti-VEGF) therapy has improved the visual outcome and provided an evolution in the tre...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tahmineh Motevasseli, Saeed Mohammadi, Fatemeh Abdi, William R. Freeman
Formato:	article
Lenguaje:	EN
Publicado:	Knowledge E 2021
Materias:	anti-vascular endothelial growth factor brolucizumab wet age-related macular degeneration Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/ac4e96759db54030b0e8016111a295ae
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
por: Yannuzzi NA, et al.
Publicado: (2019)

Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study
por: Chakraborty D, et al.
Publicado: (2021)

Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice
por: Andrea Montesel, et al.
Publicado: (2021)

A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK
por: Hykin P, et al.
Publicado: (2016)

Management of neovascular age-related macular degeneration: Taiwan expert consensus
por: Ling Yeung, et al.
Publicado: (2021)

Vision Recovery Velocity, Momentum and Acceleration: Advanced Vitreoretinal Analytics as Measure of Treatment Efficacy for Neovascular Age-Related Macular Degeneration
por: Almeida DRP, et al.
Publicado: (2021)

Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning
por: Miyamoto N, et al.
Publicado: (2017)

Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration
por: Cheema MR, et al.
Publicado: (2021)

Neovascular age-related macular degeneration without drusen in the fellow eye: clinical spectrum and therapeutic outcome
por: Chung WH, et al.
Publicado: (2016)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
por: Nudleman E, et al.
Publicado: (2016)

Treatment of neovascular age-related macular degeneration with anti-VEGF agents: retrospective analysis of 5-year outcomes
por: Pedrosa AC, et al.
Publicado: (2016)

Physician, patient, and caregiver experience of different wet age-related macular degeneration anti-VEGF treatment regimens in Japan: a qualitative assessment
por: Iida T, et al.
Publicado: (2016)

Incidence of Glaucoma or Ocular Hypertension After Repeated Anti-Vascular Endothelial Growth Factor Injections for Macular Degeneration
por: Wingard JB, et al.
Publicado: (2019)

Visual Outcome and Treatment Frequency of Anti-VEGF Therapy Using the Treat-and-Extend and Treatment Cessation Regimen for Exudative Age-Related Macular Degeneration and Pachychoroid Neovasculopathy
por: Kinoshita T, et al.
Publicado: (2021)

Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date
por: Chen ER, et al.
Publicado: (2020)

Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration
por: Balaratnasingam C, et al.
Publicado: (2015)

The Impact of Non-Ophthalmic Factors on Intravitreal Injections During the COVID-19 Lockdown
por: Ashrafzadeh S, et al.
Publicado: (2021)

Factors Affecting Compliance to Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in a Cohort of Jordanian Patients
por: Abu-Yaghi NE, et al.
Publicado: (2020)

Treatment Course of Patients with Exudative Age-Related Macular Degeneration Using Ocular Hypotensives
por: Modjtahedi BS, et al.
Publicado: (2020)

A Multicenter, Cross-Sectional Study of the Incidence of Major Macular Diseases That Cause Visual Impairment and Require Therapeutic Intervention in Greece: The ADVICE Study
por: Karagiannis DA, et al.
Publicado: (2020)

Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration
por: Taipale C, et al.
Publicado: (2018)

Trends in Real-World Neovascular AMD Treatment Outcomes in the UK
por: Mehta H, et al.
Publicado: (2020)

Synthetic anti-angiogenic genomic therapeutics for treatment of neovascular age-related macular degeneration
por: Jing Wang, et al.
Publicado: (2021)

Treatment patterns in diabetic macular edema in Taiwan: a retrospective chart review
por: Sheu SJ, et al.
Publicado: (2018)

Genetics and age-related macular degeneration: a practical review for the clinician
por: Schwartz SG, et al.
Publicado: (2016)

Integrated results from the COPERNICUS and GALILEO studies
por: Pielen A, et al.
Publicado: (2017)

Guidelines for the Management of Center-Involving Diabetic Macular Edema: Treatment Options and Patient Monitorization
por: Figueira J, et al.
Publicado: (2021)

Acquired Vitelliform Macular Degeneration: Characteristics and Challenges of Managing Subretinal Fluid
por: Joseph Juliano, et al.
Publicado: (2021)

Effect of intravitreal aflibercept on corneal endothelial cells: a 6-month follow-up study
por: Muto T, et al.
Publicado: (2019)

Intravitreal pegaptanib for the treatment of ischemic diabetic macular edema
por: Kiire CA, et al.
Publicado: (2015)

Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization
por: Tan CS, et al.
Publicado: (2017)

Baseline Subfoveal Choroidal Thickness as a Predictor for Response to Short-Term Intravitreal Bevacizumab Injections in Diabetic Macular Edema
por: Dweikat A, et al.
Publicado: (2021)

The burden of neovascular age-related macular degeneration: a patient’s perspective
por: Spooner KL, et al.
Publicado: (2018)

Quantifying Conflict of Interest in the Choice of Anti-VEGF Agents
por: Browning DJ, et al.
Publicado: (2021)

Polypoidal choroidal vasculopathy (PCV): the 4-year review of the real-life treatment experiences
por: Ratanasukon M, et al.
Publicado: (2018)

The emotional and physical impact of wet age-related macular degeneration: findings from the wAMD Patient and Caregiver Survey
por: Varano M, et al.
Publicado: (2016)

Prevalence of and risk factors for age-related macular degeneration in Nepal: the Bhaktapur Retina Study
por: Thapa R, et al.
Publicado: (2017)

Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials
por: Dugel PU, et al.
Publicado: (2016)

Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration? A Prospective, Randomized, Pilot Study
por: Solomon SD, et al.
Publicado: (2021)

Comment on: “Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes”
por: Kaya A
Publicado: (2016)